Charles River Laboratories International Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Charles River Laboratories International Inc Company

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Inc Info



Ticker SymbolCRL

Company nameCharles River Laboratories International Inc

IPO dateJun 23, 2000

CEOMr James C. Foster

Number of employees18600

Security typeOrdinary Share

Fiscal year-endJun 23

Address251 Ballardvale St

CityWILMINGTON

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code01887

Phone17812226000

Websitehttps://www.criver.com/

Ticker SymbolCRL

IPO dateJun 23, 2000

CEOMr James C. Foster

Company Executives of Charles River Laboratories International Inc



Name

Name/Position

Position

Shareholding

Change

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

267.96K

+6.88%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

57.72K

+24.38%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

17.89K

+48.67%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

12.88K

+69.56%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

12.48K

-8.77%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+23.86%

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.96K

+31.35%

Ms. Reshema Kemps-Polanco

Independent Director

2.59K

+155.42%

Dr. Craig B. Thompson, M.D.

Independent Director

2.41K

+64.49%

Mr. Abraham N. (Abe) Ceesay

Independent Director

946.00

--

Name

Name/Position

Position

Shareholding

Change

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

267.96K

+6.88%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

57.72K

+24.38%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

17.89K

+48.67%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

12.88K

+69.56%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

12.48K

-8.77%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+23.86%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

DSA

618.03M

59.88%

RMS

213.27M

20.66%

Manufacturing

200.84M

19.46%

By RegionUSD

Name

Revenue

Proportion

United States

549.86M

53.27%

Europe

281.86M

27.31%

Canada

135.59M

13.14%

Asia Pacific (Region)

54.50M

5.28%

Other

10.33M

1.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

DSA

618.03M

59.88%

RMS

213.27M

20.66%

Manufacturing

200.84M

19.46%

Shareholding Stats

Updated: Wed, Oct 8

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

11.79%

Wellington Management Company, LLP

7.66%

BlackRock Institutional Trust Company, N.A.

5.59%

Allspring Global Investments, LLC

4.43%

State Street Investment Management (US)

3.78%

Other

66.77%

Shareholders

Proportion

The Vanguard Group, Inc.

11.79%

Wellington Management Company, LLP

7.66%

BlackRock Institutional Trust Company, N.A.

5.59%

Allspring Global Investments, LLC

4.43%

State Street Investment Management (US)

3.78%

Other

66.77%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.53%

Investment Advisor/Hedge Fund

41.31%

Hedge Fund

9.40%

Research Firm

5.95%

Bank and Trust

2.19%

Pension Fund

1.50%

Individual Investor

1.05%

Sovereign Wealth Fund

1.04%

Private Equity

0.20%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1382

51.79M

105.23%

-10.91M

2025Q2

1399

56.14M

114.06%

-4.38M

2025Q1

1435

55.38M

112.72%

-5.93M

2024Q4

1423

54.85M

107.26%

-4.35M

2024Q3

1392

53.78M

105.14%

-5.12M

2024Q2

1399

54.00M

104.84%

-4.00M

2024Q1

1393

53.76M

104.37%

-4.04M

2023Q4

1424

53.56M

104.42%

-4.24M

2023Q3

1446

53.56M

104.42%

-3.98M

2023Q2

1427

52.88M

103.32%

-3.95M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

5.80M

11.79%

-293.30K

-4.81%

Jun 30, 2025

Wellington Management Company, LLP

3.77M

7.66%

-517.21K

-12.07%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.75M

5.59%

-156.85K

-5.39%

Jun 30, 2025

Allspring Global Investments, LLC

2.29M

4.66%

+516.52K

+29.11%

Jun 30, 2025

State Street Investment Management (US)

1.86M

3.78%

-43.84K

-2.30%

Jun 30, 2025

Nomura Securities Co., Ltd.

1.57M

3.19%

+967.65K

+160.84%

Jun 30, 2025

Ariel Investments, LLC

1.42M

2.88%

+314.57K

+28.58%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.23M

2.5%

-31.43K

-2.49%

Jun 30, 2025

Harris Associates L.P.

1.16M

2.36%

+1.16M

--

Jun 30, 2025

Invesco Capital Management LLC

1.09M

2.22%

+110.27K

+11.23%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

First Trust NASDAQ Pharmaceuticals ETF

2.13%

Invesco S&P 500 Equal Weight Health Care ETF

1.78%

VanEck Biotech ETF

1.62%

Schwab Ariel Opportunities ETF

1.61%

ROBO Global Healthcare Technology & Innovation ETF

1.56%

Franklin Genomic Advancements ETF

1.37%

iShares Health Innovation Active ETF

1.29%

Principal Quality ETF

1.01%

WisdomTree US Value Fund

0.98%

Invesco S&P 500 High Beta ETF

0.93%

First Trust NASDAQ Pharmaceuticals ETF

Proportion2.13%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.78%

VanEck Biotech ETF

Proportion1.62%

Schwab Ariel Opportunities ETF

Proportion1.61%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.56%

Franklin Genomic Advancements ETF

Proportion1.37%

iShares Health Innovation Active ETF

Proportion1.29%

Principal Quality ETF

Proportion1.01%

WisdomTree US Value Fund

Proportion0.98%

Invesco S&P 500 High Beta ETF

Proportion0.93%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data